Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 2/20 | 0.35 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6735961 | 0.91 | MMP13 (0.36) | MMP13SLC22A8MAPK1 | |
| SCHEMBL6471042 | 0.89 | MMP13 (0.36) | MMP13SLC22A8MAPK1 | |
| SCHEMBL6913360 | 0.89 | PTGER4 (0.41) | MMP13SLC22A8 | |
| SCHEMBL6471978 | 0.89 | MMP13 (0.36) | MMP13SLC22A8MAPTMAPK1 | |
| SCHEMBL6461412 | 0.89 | MMP13 (0.36) | MMP13SLC22A8MAPK1 | |
| SCHEMBL6730190 | 0.87 | MMP13 (0.40) | MMP13SLC22A8 | |
| SCHEMBL6912473 | 0.85 | MMP13 (0.38) | MMP13SLC22A8MAPK1 | |
| SCHEMBL6916599 | 0.85 | MMP13 (0.38) | MMP13SLC22A8MAPTRXFP1MAPK1 | |
| SCHEMBL7035441 | 0.85 | MMP13 (0.35) | MMP13SLC22A8MAPK1 | |
| SCHEMBL6733045 | 0.84 | MMP13 (0.37) | MMP13SLC22A8MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | HARTER WILLIAM GLEN (US) | 2003-01-02 | — | — | US | claimed |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| US-6596798-B1 | method for forming a functionalized polymer comprising the steps of providing a living lithium polymer; and terminating the living lithium polymer with an oxazoline compound according to the following formula (I): | BRIDGESTONE CORPORATION (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20030125477-A1 | Preparation of low hysteresis rubber by reacting a lithium polymer with oxazoline compounds | BRIDGESTONE CORPORATION (JP) | 2003-07-03 | — | — | US | disclosed |
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | HARTER WILLIAM GLEN (US) | 2003-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | MMP13, MMP3, MMP25 | MMP13 1/4885SLC22A8 605/4885TP53 4652/4885 |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | MMP13, MMP11, MMP10 | MMP13 1/4885SLC22A8 159/4885TP53 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.